Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have received an average rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $11.50.

A number of research firms recently commented on KLRS. Citizens Jmp assumed coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price objective on the stock. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 15th. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Raymond James Financial assumed coverage on shares of Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating on the stock.

Institutional Investors Weigh In On Kalaris Therapeutics

Several large investors have recently added to or reduced their stakes in KLRS. Johnson Financial Group Inc. acquired a new position in Kalaris Therapeutics in the third quarter valued at approximately $58,000. Bridgeway Capital Management LLC bought a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at $130,000. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics during the 2nd quarter valued at $65,000. Fortis Capital Advisors LLC bought a new position in Kalaris Therapeutics during the third quarter worth $231,000. Finally, Belpointe Asset Management LLC bought a new position in Kalaris Therapeutics during the third quarter worth $231,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Stock Performance

Shares of NASDAQ:KLRS opened at $10.06 on Tuesday. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90. The firm has a market cap of $188.12 million, a PE ratio of -2.67 and a beta of -0.04. The firm’s fifty day moving average is $6.10 and its 200-day moving average is $4.40.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.02.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.